Pre- and postnatal administration of Lactobacillus reuteri decreases TLR2 responses in infants

Research

Anna Forsberg, Thomas R Abrahamsson, Bengt Björkstén and Maria C Jenmalm

Author Affiliations

For all author emails, please log on.

Clinical and Translational Allergy 2014, 4:21  doi:10.1186/2045-7022-4-21

Published: 25 June 2014

Abstract (provisional)

Background

Mice models indicate that intact Toll like receptor (TLR) signaling may be essential for the allergy protective effects of diverse bacterial exposure observed in clinical trials and epidemiological studies. Probiotic supplementation with Lactobacillus reuteri from pregnancy week 36 and to the infant through the first year of life decreased the prevalence of IgE-associated eczema at two years (ClinicalTrials.gov NCT01285830). The effect of this supplementation on innate immune responses to bacterial products and the expression of associated TLRs were explored.

Methods

Blood mononuclear cells were collected at birth, 6, 12 and 24 months from 61 infants and cultured with TLR2, 4 and 9 ligands. Cytokine and chemokine secretion was determined as well as TLR2, 4 and 9 mRNA expression.

Results

Probiotic supplementation was associated with decreased LTA (lipoteichoic acid) induced CCL4, CXCL8, IL-1beta and IL-6 responses at 12 months and decreased CCL4 and IL-1beta secretion at 24 months. TLR2 mRNA expression was not affected by probiotic treatment.

Conclusions

Decreased responses to TLR2, the main receptor for LTA from Gram positive bacteria, in probiotic treated children seem to be dependent on factors downstream of TLR mRNA expression.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.